162 related articles for article (PubMed ID: 20728981)
21. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
[TBL] [Abstract][Full Text] [Related]
22. [Recent advances in studies of ovarian serous and mucinous borderline ovarien tumors].
Shao HL; Shen DH
Zhonghua Bing Li Xue Za Zhi; 2006 Mar; 35(3):173-5. PubMed ID: 16630508
[No Abstract] [Full Text] [Related]
23. Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma.
Shvartsman HS; Sun CC; Bodurka DC; Mahajan V; Crispens M; Lu KH; Deavers MT; Malpica A; Silva EG; Gershenson DM
Gynecol Oncol; 2007 Jun; 105(3):625-9. PubMed ID: 17320156
[TBL] [Abstract][Full Text] [Related]
24. Recurrence and prognostic factors in borderline ovarian tumors.
Ayhan A; Guvendag Guven ES; Guven S; Kucukali T
Gynecol Oncol; 2005 Sep; 98(3):439-45. PubMed ID: 16009407
[TBL] [Abstract][Full Text] [Related]
25. [Evaluation of radiotherapy for state I ovarian carcinoma].
Sheng X; Sun J; Zhou C
Zhonghua Zhong Liu Za Zhi; 1996 Jul; 18(4):314-6. PubMed ID: 9387332
[TBL] [Abstract][Full Text] [Related]
26. [Serum level and expression of vascular epithelial growth factor in ovarian epithelial carcinoma].
Sun LX; Wu Y; Han HQ; Wang QH
Ai Zheng; 2003 Jan; 22(1):58-61. PubMed ID: 12561438
[TBL] [Abstract][Full Text] [Related]
27. Human telomerase reverse transcriptase (hTERT) expression in borderline ovarian tumors: an immunohistochemical study.
Tantbirojn P; Triratanachat S; Trivijitsilp P; Niruthisard S
J Med Assoc Thai; 2009 Mar; 92(3):308-14. PubMed ID: 19301721
[TBL] [Abstract][Full Text] [Related]
28. [Analysis of long-term prognostic factors of epithelial ovarian cancer].
Li MD; Li YJ; Huang YW; Huang H
Ai Zheng; 2004 Nov; 23(11):1306-10. PubMed ID: 15522179
[TBL] [Abstract][Full Text] [Related]
29. Histological classification of ovarian cancer.
Kaku T; Ogawa S; Kawano Y; Ohishi Y; Kobayashi H; Hirakawa T; Nakano H
Med Electron Microsc; 2003 Mar; 36(1):9-17. PubMed ID: 12658347
[TBL] [Abstract][Full Text] [Related]
30. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors.
Ortiz BH; Ailawadi M; Colitti C; Muto MG; Deavers M; Silva EG; Berkowitz RS; Mok SC; Gershenson DM
Cancer Res; 2001 Oct; 61(19):7264-7. PubMed ID: 11585764
[TBL] [Abstract][Full Text] [Related]
31. Peritoneal recurrences might be less common in advanced stage serous borderline ovarian tumors that were treated by laparotomy.
Vandenput I; Amant F; Vergote I
Gynecol Oncol; 2005 Sep; 98(3):523; author reply 524-5. PubMed ID: 16054202
[No Abstract] [Full Text] [Related]
32. A phase II clinical trial of topotecan in Japanese patients with relapsed ovarian carcinoma.
Aoki D; Katsumata N; Nakanishi T; Kigawa J; Fujiwara K; Takehara K; Kamiura S; Hiura M; Hatae M; Sugiyama T; Ochiai K; Noda K
Jpn J Clin Oncol; 2011 Mar; 41(3):320-7. PubMed ID: 20974678
[TBL] [Abstract][Full Text] [Related]
33. The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters.
Lin CK; Chao TK; Yu CP; Yu MH; Jin JS
APMIS; 2009 Mar; 117(3):162-75. PubMed ID: 19245589
[TBL] [Abstract][Full Text] [Related]
34. Borderline ovarian tumors in reproductive-age women. Fertility-sparing surgery and outcome.
Chan JK; Lin YG; Loizzi V; Ghobriel M; DiSaia PJ; Berman ML
J Reprod Med; 2003 Oct; 48(10):756-60. PubMed ID: 14619640
[TBL] [Abstract][Full Text] [Related]
35. The current status of surgical staging of ovarian serous borderline tumors.
Lin PS; Gershenson DM; Bevers MW; Lucas KR; Burke TW; Silva EG
Cancer; 1999 Feb; 85(4):905-11. PubMed ID: 10091769
[TBL] [Abstract][Full Text] [Related]
36. Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long-term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma.
Kennedy AW; Hart WR
Cancer; 1996 Jul; 78(2):278-86. PubMed ID: 8674004
[TBL] [Abstract][Full Text] [Related]
37. [Clinical characteristics of borderline ovarian tumors and stage I epithelial ovarian cancer: an analysis of 143 cases].
Zhao Y; Wang Y; Shen Dh; Song Rn; Xu Q; Li Y; Cui H; Tang J; Wei Lh
Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Feb; 43(1):123-8. PubMed ID: 21321635
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors.
Gershenson DM; Deavers M; Diaz S; Tortolero-Luna G; Miller BE; Bast RC; Mills GB; Silva EG
Clin Cancer Res; 1999 Dec; 5(12):4053-8. PubMed ID: 10632339
[TBL] [Abstract][Full Text] [Related]
39. Surgery of borderline tumors of the ovary: retrospective comparison of short-term outcome after laparoscopy or laparotomy.
Ødegaard E; Staff AC; Langebrekke A; Engh V; Onsrud M
Acta Obstet Gynecol Scand; 2007; 86(5):620-6. PubMed ID: 17464594
[TBL] [Abstract][Full Text] [Related]
40. [Morphometrical and immunohistochemical criteria of prognosis in patients with serous and mucinous ovarian carcinoma].
Kolosov AE; Novichkov EV
Arkh Patol; 2003; 65(5):29-32. PubMed ID: 14664145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]